Integril 0.75 mg/ml iv injection
Generic: Eptifibatide
Company: Incepta Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.
Reviewed by: not listed yet. Source: not listed yet.
Last updated September 7, 2024.
Generic: Eptifibatide
Company: Incepta Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.
Reviewed by: not listed yet. Source: not listed yet.
Last updated September 7, 2024.
Sorted by price per iv injection. Ask your pharmacist before you switch brands.
Prices as listed on BestinMeds.
No price is listed for this strength yet.
Advertisement
What this medicine is for, how to take it, and what to watch for.
Read the full Eptifibatide guide
Unstable angina Eptifibatide is indicated in- Patients with acute coronary syndrome (unstable angina/non-ST- segment elevation myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). Patients undergoing PCI, including those undergoing intracoronary stenting.
Patients with ACS (Acute Coronary Syndrome): Normal renal function: 180 μg/kg IV bolus of as soon as possible following diagnosis followed by a continuous infusion of 2 μg/kg/min. Creatinine clearance: 180 μg/kg IV bolus of as soon as possible following diagnosis followed by a continuous infusion of 1 μg/kg/min. Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours. If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. Patients with PCI ( Percutaneous Coronary Intervention): Normal renal function: 180 μg/kg IV bolus immediately before PCI followed by a continuous infusion of 2 μg/kg/min & a second bolus of 180 μg/kg (given 10 minutes after the first bolus) Creatinine clearance: 180 μg/kg IV bolus immediately before PCI followed by a continuous infusion of 1 μg/kg/min & a second bolus of 180 μg/kg (given 10 minutes after the first bolus) Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. In patients who undergo CABG surgery, INTEGRILIN infusion should be discontinued prior to surgery.
Bleeding is the most common adverse effect. Adverse reactions include intracranial hemorrhage & stroke, thrombocytopenia, allergic reactions and hypotension.
This information is not available. Ask your doctor or pharmacist.
Pregnancy: Category B. Animal studies revealed no evidence of harm to the fetus due to Integril. There are, however, no adequate and well-controlled studies in pregnant women with Integril. Lactating Mothers: It is not known whether Integril is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Integril is administered to a nursing mother.
Eptifibatide is a cyclic heptapeptide containing six amino acids and one mercaptopropionyl (des-amino cysteinyl) residue. Integril binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa.
• In various clinical studies, eptifibatide was used concomitantly with unfractionated heparin and aspirin. In another study, clopidogrel or ticlopidine were used routinely starting the day of PCI. Because eptifibatide inhibits platelet aggregation, caution should be employed when it is used with other drugs that affect hemostasis, including thrombolytics, oral anticoagulants, NSAIDS and dipyridamole. To avoid potentially additive pharmacologic effects, concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided • Enoxaparin did not alter the pharmacokinetics of Integril
Use in Children: Safety and effectiveness of Integril in pediatric patients have not been studied.
• There has been only limited experience with overdosage of Integril. Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits, and petechial hemorrhages in the femoral and abdominal areas of monkeys. • From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis.
Anti-platelet drugs
• Vials should be stored refrigerated at 2-8° C • Vials may be transferred to room temperature storage for up to 2 months. • Unused portion left in the vial should be discarded. • Vials should be protected from light until administration.
BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.
Advertisement
No other Integril products are listed yet.
Advertisement